Eli Lilly and Company (LLY)

239.46
NYSE
Prev Close 240.42
Day Low/High 235.12 / 241.53
52 Wk Low/High 178.58 / 283.90
Exchange NYSE
Shares Outstanding 956.59B
Market Cap 229.98B
P/E Ratio 33.79
Div & Yield N.A. (N.A)

Latest News

Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales

Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales

Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.

Eli Lilly Rated at BMO

October Rebound, Pricing In the Past, Tesla Hertz So Good, Space, Facebook Q&A

October Rebound, Pricing In the Past, Tesla Hertz So Good, Space, Facebook Q&A

Markets are pricing in some fiscal policy, but it's not what a lot of pundits think.

What to Watch Next Week

Next Week (Selected Macro) Monday   AM: PM:   Tuesday   AM: , , , , , PM: , , ,   Wednesday   AM: , , , PM: , ,   Thursday   AM: PM: , ,   Friday   AM: , PM: none Next Week (Selected Macro)   Monday: Dallas Fed Manufacturing Index   Tuesday: Case-Sh...

Eli Lilly Raised to Buy at Citi

While This Market Action Makes for Some Tough Trading, It's Nothing Unusual

While This Market Action Makes for Some Tough Trading, It's Nothing Unusual

Pockets of speculative trading are narrower, but the appetite for action has not disappeared.

Stall Speed? Jobs Gut Punch, Taiwan Worries, Mu Variant, Trading AbbVie

Stall Speed? Jobs Gut Punch, Taiwan Worries, Mu Variant, Trading AbbVie

What if areas of expected growth in labor market demand moving forward do not materialize?

Pfizer's Charts Suggest a Strong Rally Ahead

Pfizer's Charts Suggest a Strong Rally Ahead

Here are our latest price targets.

Jim Cramer: The Drug Cos. Are at Full Strength

Jim Cramer: The Drug Cos. Are at Full Strength

We're seeing a group move in pharma right now, so let's sort it out, pill by pill.

Market on Eggshells, Masking Up, ISM, Pfizer and Moderna Just Getting Started

Market on Eggshells, Masking Up, ISM, Pfizer and Moderna Just Getting Started

Doesn't the Fed now have to taper asset purchases simply to avoid becoming an even greater force in these markets?

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.

Eli Lilly Is Going Strong: Here's How to Play It

Eli Lilly Is Going Strong: Here's How to Play It

Let's check out the LLY charts amid FDA approval of the company's Alzheimer's drug.

Jim Cramer: It's a Jailbreak and the Stocks Are Busting Out

Jim Cramer: It's a Jailbreak and the Stocks Are Busting Out

This market is moving in so many areas that you have to marvel at how it's even possible -- even if the Russell Rebalancing could change all that on Friday.

Biogen's Japanese Partner on Alzheimer's Drug Set for Gains

Biogen's Japanese Partner on Alzheimer's Drug Set for Gains

Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.

Jim Cramer: Here's What Can Go Higher

Jim Cramer: Here's What Can Go Higher

Let's look at the companies that can go up, and the ones that can't.

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market

Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'

My Beautiful Balloon, Unmasking the Market, Crypto Risk, Preparing for Powell

My Beautiful Balloon, Unmasking the Market, Crypto Risk, Preparing for Powell

With the economy apparently growing robustly, the Fed has to watch how the president's plans play out in terms of the size and scope of deficit spending.

My Favorite Day of the Month: Options Expiration Day

My Favorite Day of the Month: Options Expiration Day

I have become a huge devotee of this simple option strategy. Here are two recent examples from this week.

Jim Cramer: We've Got a Boom ... and a Bust

Jim Cramer: We've Got a Boom ... and a Bust

Let's look at this impossible move on the market -- and why health care could be coming off life support.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Let's review the charts and indicators.

Here's How I'm Going to Fix My Position in Merck

Here's How I'm Going to Fix My Position in Merck

This is my fifth worst performing position in a book that contains 62 open positions.

Jim Cramer: There's Good Risk and Bad Risk

Jim Cramer: There's Good Risk and Bad Risk

Here's the kind I like to buy -- and the vetted stocks that you can play on 'good' risk.

Very Scary Ghost Stories, the Case for Hard Assets, Latest on Robinhood

Very Scary Ghost Stories, the Case for Hard Assets, Latest on Robinhood

One of the scary stories deals with what could happen if there was coordinated gaming of the U.S. dollar.

Jim Cramer: The Market Now Acts Like a Market of Stocks Than a Bushel or a Peck

Jim Cramer: The Market Now Acts Like a Market of Stocks Than a Bushel or a Peck

There was a period before the time of commoditization where individual elan and corporate dominance meant something. And that's back.

Jim Cramer: Here Are the Biden Stocks

Jim Cramer: Here Are the Biden Stocks

As power has changed hands in the White House, we can expect these names -- and themes -- to benefit.

Jim Cramer: Looking for Gold? Go With Science

Jim Cramer: Looking for Gold? Go With Science

A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.